| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于不向下修正"益丰转债"转股价格的公告 重要内容提示： 自 2025 年 9 月 17 日至 2025 年 10 月 15 日，公司股票的收盘价已在任意 连续三十个交易日中至少有十五个交易日低于当期转股价格的 85%，已触发"益 丰转债"转股价格修正条款。 公司于 2025 年 10 月 15 日召开第五届董事会第二十三次会议，审议通过 了《关于不向下修正"益丰转债"转股价格的议案》。公司决定本次不向下修正 "益丰转债"的转股价格，并且在未来 3 个月内（即 2025 年 10 月 16 日至 2026 年 1 月 15 日），公司股价若再次触发此条款，亦不向下修正"益丰转债"的转 股价格。下一触发转股价格修正条款的期间从 2026 年 1 月 16 日起重新计算，若 公司股价再次触发"益丰转债"的转股价格向下修正条款，届时公司董事会将再 次召开会议决定是否行使"益丰转债"转股价格向下修正的权利 ...

Investment Rating - The industry investment rating is "Outperform the Market" [4][36]. Core Insights - The offline pharmacy sector is currently under pressure from healthcare policies and is in a recovery phase, with a focus on improving individual store operational efficiency, which is beneficial for long-term industry health [2][28]. - The offline pharmacy index has seen a decline of 1.70% in September, underperforming the broader market, primarily due to concerns over patient traffic and healthcare revenue loss amid stringent healthcare funding regulations [7][28]. - The valuation of the offline pharmacy sector is at a historical low, with a price-to-earnings ratio of 23.01 as of October 10, 2025, indicating a significant drop from previous years [23][28]. Summary by Sections Market Review - In September, the pharmaceutical sector underperformed the market, with the pharmaceutical index down by 1.71% [11]. - The offline pharmacy sector's performance was notably weak, with a decline of 1.70% compared to other sub-sectors [16]. - Most listed companies in the offline pharmacy sector saw their stock prices drop in September, with significant declines in companies like Huaren Health and Shuyupingmin [21]. Monthly Insights on Offline Pharmacies - The offline pharmacy sector has been underperforming since the second half of 2024 due to ongoing pressure from healthcare policies and concerns about revenue loss [28]. - The long-term trend of prescription outflow remains unchanged, which is expected to drive the growth of the pharmacy sector [28]. - Leading pharmacies are well-positioned to benefit from prescription outflow due to their strong service capabilities and supply chain systems [28]. Valuation Analysis - As of October 10, 2025, the offline pharmacy index's price-to-earnings ratio is at a five-year low, reflecting a significant decline in market confidence [23][28].

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, particularly focusing on innovative drugs and the recovery of left-side sectors as the biggest investment opportunities for the year [5][14]. Core Insights - The innovative drug sector is expected to continue its upward trend, with BD (business development) activities anticipated to catalyze market movements. The upcoming ESMO conference (October 17-21) is highlighted as a key event for clinical data disclosures from domestic innovative drug companies [2][13]. - The report emphasizes the importance of recent Nobel Prize discoveries related to peripheral immune tolerance, which are relevant to the development of new therapies in oncology and autoimmune diseases. This underscores the significance of innovation in these fields [40][50]. - The report notes that the CXO industry in China is entering a recovery phase, with improvements expected in industry orders, capacity utilization, and performance metrics due to enhanced domestic investment and financing data [2][5]. Summary by Sections Innovative Drugs - The innovative drug sector has seen a recent pullback, but the long-term upward trend remains intact. The report suggests that the market is awaiting further BD catalysts and highlights the importance of upcoming clinical data from the ESMO conference [2][13]. - The report indicates that the overall sentiment in the innovative drug sector is still positive, with a focus on potential breakthroughs in cancer and autoimmune therapies following the recent Nobel Prize discoveries [40][50]. Biologics - Novo Nordisk announced an agreement to acquire Akero for $4.7 billion, with Akero's FGF21 analog EFX showing promise as a leading therapy for metabolic dysfunction-related fatty liver disease (MASH) [3][51]. - The report suggests that EFX is the only drug in Phase 2 trials demonstrating significant fibrosis regression in F4 patients, highlighting the need for continued attention to developments in this area [51][57]. Medical Devices - The commercialization of innovative products is accelerating, with domestic replacements making significant progress. For instance, MicroPort's Tumi laparoscopic surgical robot has surpassed 100 global orders and is leading the domestic market share [4][58]. - The report notes that the Tumi robot has received market access in over 60 countries and regions, with a strong presence in high-end markets such as Europe [60][62]. Traditional Chinese Medicine - There has been a continuous increase in new drug IND and NDA applications for traditional Chinese medicine, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [3][64]. - The report highlights ongoing policy support for traditional Chinese medicine, which is expected to drive further innovation and development in this sector [64][65].

关于募集资金委托理财进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-098 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 本次赎回产品基本情况 | 产品名称 | 共赢智信利率挂钩人民币结构性存款 期 A07652 | | | --- | --- | --- | | 受托方名称 | 中信银行股份有限公司 | | | 购买金额 | 6,400.00 | 万元 | | 产品期限 | 90 天 | | | 产品名称 | 智汇系列进取型看涨三层区间 天结构性存款 91 | | | --- | --- | --- | | 受托方名称 | 招商银行股份有限公司 | | | 购买金额 | 4,000.00 | 万元 | | 产品期限 | 天 91 | | | 产品名称 | 利多多公司稳利 25JG3364 期(月月滚利特供款 C)人民币对 公结构性存款 | ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-097 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经上海证券交易所自律监管决定书〔2024〕32号文同意，公司179,743.20 万元可转换公司债券已于2024年3月27日起在上海证券交易所挂牌交易，债券 简称"益丰转债"，债券代码"113682"。 根据有关规定和《益丰大药房连锁股份有限公司向不特定对象发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）的约定，公司本次发行 的"益丰转债"自2024年9月9日起可转换为公司股份。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有面值 181,000 元"益丰转 债"转为公司 A 股普通股，累计转股股数为 5,509 股，占"益丰转债"转股前 公司已发行普通股股份总额的 0.0005%。 ...

Investment Rating - The industry rating is "Positive" (maintained) [7] Core Views - The report highlights that the domestic innovative drug sector is entering a phase of "engineer dividend" realization, with improved profitability and valuation breakthroughs expected [1] - The CXO sector is showing signs of recovery, with a positive outlook on CDMO commercialization orders and clinical CRO investment opportunities [2] - The upstream research sector is anticipated to benefit from a downward interest rate cycle and a recovery in global new drug development demand, with recommended stocks including Haoyuan Pharmaceutical and Bid Pharma [3] - The medical device sector is expected to experience a recovery cycle, particularly for high-value consumables and medical equipment companies, with recommendations for companies like Aikang Medical and Mindray Medical [4] - The traditional Chinese medicine sector is projected to see an earnings inflection point, with a favorable outlook for the second half of 2025 [5] - The report favors leading pharmacy chains with superior management capabilities, recommending companies such as Dazhonglin and Yifeng Pharmacy [6] - The pharmaceutical distribution sector is expected to improve, with a focus on low-positioned value and innovative business opportunities [7] Summary by Sections Innovative Drugs - Positive outlook on profitability improvement and valuation breakthroughs due to recognition by multinational corporations [1] CXO - Recovery in the sector with ongoing commercialization of small and large molecule CDMO orders [2] Upstream Research - Anticipated performance elasticity and new business expansion opportunities [3] Medical Devices - Significant growth potential in high-value consumables and medical equipment sectors [4] Traditional Chinese Medicine - Expected earnings growth and increased market interest due to improved fundamentals [5] Pharmacies - Favorable view on pharmacy chains with strong management and adaptability [6] Pharmaceutical Distribution - Positive trends in the sector with potential for operational improvements and value re-evaluation [7]

Core Viewpoint - Yifeng Pharmacy's stock price has shown a slight increase of 2.94% year-to-date, but has experienced a decline in recent trading days, indicating potential volatility in the market [1][2]. Financial Performance - As of June 30, Yifeng Pharmacy reported a revenue of 11.722 billion yuan for the first half of 2025, a year-on-year decrease of 0.35%, while the net profit attributable to shareholders was 880 million yuan, reflecting a year-on-year growth of 10.32% [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.852 billion yuan, with 1.946 billion yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders increased by 7.70% to 21,600 as of June 30, 2025, while the average circulating shares per person decreased by 7.15% to 56,081 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, holding 237 million shares, a decrease of approximately 35.39 million shares from the previous period [3]. Market Activity - On October 9, Yifeng Pharmacy's stock price fell by 2.15% to 24.12 yuan per share, with a trading volume of 34.5745 million yuan and a turnover rate of 0.12% [1]. - The stock has seen a net inflow of 61,400 yuan from main funds, with large orders accounting for 7.94% of purchases and 7.76% of sales [1].

Group 1 - The core viewpoint of the articles highlights that Yifeng Pharmacy has been awarded the highest AAA rating in the 2024 ESG report by MSCI, making it the only Chinese company to achieve this in the global healthcare service sector [1] - Yifeng Pharmacy's 2024 ESG report indicates significant achievements in carbon emission reduction and energy-saving measures, contributing to the industry's low-carbon transition [1] - The company has implemented a systematic carbon reduction strategy and integrated carbon performance into its supplier evaluation criteria, establishing a comprehensive green supply chain management system [1] Group 2 - Yifeng Pharmacy places a strong emphasis on employee career development, safety, and health management, fostering a sense of belonging and respect among employees [2] - The company utilizes digital technology to enhance service quality for customers, addressing the issue of uniformity in pharmaceutical services through personalized service plans based on user profiling [2] - As of June 30, Yifeng Pharmacy has built a member database of 110 million individuals, significantly improving health management quality, especially for chronic disease patients [2]

Group 1 - The report indicates that the Federal Reserve's resumption of interest rate cuts may lead to increased foreign investment in China's export-advantaged assets, particularly in high-end manufacturing sectors such as new energy, chemicals, and pharmaceuticals [1][13] - The "anti-involution" policy in China is expected to enhance the financial returns of the manufacturing sector, with a focus on high-end manufacturing capital expenditure (CAPEX) expansion since 2019, which solidifies global export competitiveness [2][14] - The report suggests that cross-border capital is accelerating its return to China, leading to a "re-inflation bull market" as China's net export scale rises and the RMB enters a long-term appreciation cycle [3][15] Group 2 - The report anticipates a shift in the A-share bull market towards consumption-driven growth, moving from an investment-driven model to one where consumption becomes the primary economic driver [4][16] - It highlights a potential "ice-fire conversion" in market dynamics, where technology sectors may lead the rally, followed by export-oriented high-end manufacturing, and eventually consumer sectors [5][17] Group 3 - The report recommends a stock portfolio for October 2025, including companies such as Dongfang Tower (Chemicals), Huafeng Aluminum (Non-ferrous), China Hongqiao (Non-ferrous), Luoyang Molybdenum (Non-ferrous), Dongfang Tantalum (Non-ferrous), Xinnengda (Electric New), Betta Pharmaceuticals (Pharmaceuticals), Yifeng Pharmacy (Pharmaceutical Retail), Bai'ao Intelligent (Military), Hikvision (Computers), and Luxshare Precision (Electronics) [6][11]

Core Points - Yifeng Pharmacy announced the approval of the repurchase and cancellation of part of the restricted stock from the 2022 incentive plan due to the departure, demotion, or underperformance of 5 incentive targets [2] - A total of 25,516 shares will be repurchased at a price of 14.43 RMB per share, amounting to a total repurchase fund of 368,200 RMB [2]